123 related articles for article (PubMed ID: 24601730)
21. Role of CYP2D6 Polymorphisms in the Outcome of Postoperative Pain Treatment.
Seripa D; Latina P; Fontana A; Gravina C; Lattanzi M; Savino M; Gallo AP; Melchionda G; Santini SA; Margaglione M; Copetti M; di Mauro L; Panza F; Greco A; Pilotto A
Pain Med; 2015 Oct; 16(10):2012-23. PubMed ID: 25989235
[TBL] [Abstract][Full Text] [Related]
22. CYP2D6 polymorphisms and codeine analgesia in postpartum pain management: a pilot study.
VanderVaart S; Berger H; Sistonen J; Madadi P; Matok I; Gijsen VM; de Wildt SN; Taddio A; Ross CJ; Carleton BC; Hayden MR; Koren G
Ther Drug Monit; 2011 Aug; 33(4):425-32. PubMed ID: 21743374
[TBL] [Abstract][Full Text] [Related]
23. [Genotyping of CYP2D6 and CYP2C19].
Slanar O; Drazd'áková M; Babiárová K; Pechandová K; Buzková H; Perlík F; Zima T
Cas Lek Cesk; 2007; 146(9):708-11. PubMed ID: 17966194
[TBL] [Abstract][Full Text] [Related]
24. Effects of CYP3A5, CYP2C19, and CYP2B6 on the clinical efficacy and adverse outcomes of sibutramine therapy: a crucial role for the CYP2B6*6 allele.
Hwang IC; Park JY; Ahn HY; Kim KK; Suh HS; Ko KD; Kim KA
Clin Chim Acta; 2014 Jan; 428():77-81. PubMed ID: 24262967
[TBL] [Abstract][Full Text] [Related]
25. Populations and genetic polymorphisms.
Weber WW
Mol Diagn; 1999 Dec; 4(4):299-307. PubMed ID: 10671640
[TBL] [Abstract][Full Text] [Related]
26. [Pharmacogenetic study of the response to flecainide and propafenone in patients with atrial fibrillation].
Martínez-Sellés M; Castillo I; Montenegro P; Martín ML; Almendral J; Sanjurjo M
Rev Esp Cardiol; 2005 Jun; 58(6):745-8. PubMed ID: 15970126
[TBL] [Abstract][Full Text] [Related]
27. Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes.
Singh MS; Francis PA; Michael M
Breast; 2011 Apr; 20(2):111-8. PubMed ID: 21185724
[TBL] [Abstract][Full Text] [Related]
28. Pharmacogenetic testing in the face of unclear clinical efficacy: lessons from cytochrome P450 2D6 for tamoxifen.
Peppercorn J; Hamilton E; Marcom PK; Beskow L; Lyman GH
Cancer; 2013 Oct; 119(20):3703-9. PubMed ID: 23893861
[TBL] [Abstract][Full Text] [Related]
29. [Pharmacogenetic aspects of the activity of cytochromes P450 in the metabolism of antipsychotics].
Fursa OO; Kozlovskiĭ VL
Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(4):111-22. PubMed ID: 25089317
[TBL] [Abstract][Full Text] [Related]
30. Pharmacogenetics and antipsychotics in the light of personalized pharmacotherapy.
Mihaljević-Peles A; Sagud M; Bozina N; Zivković M; Jovanović N
Psychiatr Danub; 2010 Jun; 22(2):335-7. PubMed ID: 20562776
[TBL] [Abstract][Full Text] [Related]
31. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
Zhou SF; Liu JP; Chowbay B
Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
[TBL] [Abstract][Full Text] [Related]
32. Pharmacogenetics of drug-metabolizing enzymes in Italian populations.
Serpe L; Canaparo R; Scordo MG; Spina E
Drug Metab Pers Ther; 2015 Jun; 30(2):107-20. PubMed ID: 25527811
[TBL] [Abstract][Full Text] [Related]
33. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19.
de Leon J; Armstrong SC; Cozza KL
Psychosomatics; 2006; 47(1):75-85. PubMed ID: 16384813
[TBL] [Abstract][Full Text] [Related]
34. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects.
Ingelman-Sundberg M; Sim SC; Gomez A; Rodriguez-Antona C
Pharmacol Ther; 2007 Dec; 116(3):496-526. PubMed ID: 18001838
[TBL] [Abstract][Full Text] [Related]
35. Pharmacogenetics of opioid response.
Somogyi AA; Coller JK; Barratt DT
Clin Pharmacol Ther; 2015 Feb; 97(2):125-7. PubMed ID: 25670515
[TBL] [Abstract][Full Text] [Related]
36. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes.
Mega JL; Close SL; Wiviott SD; Shen L; Hockett RD; Brandt JT; Walker JR; Antman EM; Macias WL; Braunwald E; Sabatine MS
Circulation; 2009 May; 119(19):2553-60. PubMed ID: 19414633
[TBL] [Abstract][Full Text] [Related]
37. The effect of pharmacogenetic profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to polypharmacy.
Brixner D; Biltaji E; Bress A; Unni S; Ye X; Mamiya T; Ashcraft K; Biskupiak J
J Med Econ; 2016; 19(3):213-28. PubMed ID: 26478982
[TBL] [Abstract][Full Text] [Related]
38. Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales.
Sistonen J; Fuselli S; Palo JU; Chauhan N; Padh H; Sajantila A
Pharmacogenet Genomics; 2009 Feb; 19(2):170-9. PubMed ID: 19151603
[TBL] [Abstract][Full Text] [Related]
39. Pharmacogenomics and individualized drug therapy.
Eichelbaum M; Ingelman-Sundberg M; Evans WE
Annu Rev Med; 2006; 57():119-37. PubMed ID: 16409140
[TBL] [Abstract][Full Text] [Related]
40. Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet?
Perera MA; Innocenti F; Ratain MJ
Pharmacotherapy; 2008 Jun; 28(6):755-68. PubMed ID: 18503403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
